Celldex Therapeutics CLDX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$283.65M-9.6% | -$258.76M-15.2% | -$224.53M-12.5% | -$199.61M-11.6% | -$178.85M-13.3% | ||
| $3.37M-0.4% | $3.38M-0.1% | $3.38M+1.1% | $3.35M+2.3% | $3.27M+2.9% | ||
| $35.42M-2.2% | $36.22M-2.3% | $37.09M-2.2% | $37.91M+4.3% | $36.36M+6.2% | ||
| -$11K+8.3% | -$12K+25.0% | -$16K-14.3% | -$14K-16.7% | -$12K+25.0% | ||
| $19.46M+76.4% | $11.03M-23.5% | $14.42M+78.8% | $8.07M+4.8% | $7.7M-33.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$2.98M+43.4% | -$5.26M-10.2% | -$4.77M+15.3% | ||
| -$834K-163% | $1.32M+273% | -$762K+47.2% | -$1.44M+10.1% | -$1.61M+16.6% | ||
| -$222.16M-5.3% | -$210.95M-17.5% | -$179.48M+3.6% | -$186.19M-8.6% | -$171.51M-8.7% | ||
| $4.09M+50.6% | $2.71M+24.0% | $2.19M-4.6% | $2.29M+24.7% | $1.84M-4.1% | ||
| $238.24M+14.0% | $209.07M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.51M+5.2% | $2.39M+67.6% | $1.43M-24.6% | $1.89M-65.9% | $5.54M-98.7% | ||
| —— | —— | —— | —— | —— | ||
| $4.22M-28.0% | $5.86M-29.8% | $8.34M-28.5% | $11.65M-20.8% | $14.7M-6.6% | ||
| -$834K-163% | $1.32M+273% | -$762K+47.2% | -$1.44M+10.1% | -$1.61M+16.6% | ||
| $5.03M+39.2% | $3.61M+78.1% | $2.03M-53.6% | $4.37M-44.6% | $7.89M-18.1% | ||
| —— | —— | —— | —— | —— | ||
| -$283.65M-9.6% | -$258.76M-15.2% | -$224.53M-12.5% | -$199.61M-11.6% | -$178.85M-13.3% | ||
| $2.51M+5.2% | $2.39M+67.6% | $1.43M-24.6% | $1.89M-65.9% | $5.54M-39.5% | ||
| —— | —— | —— | —— | —— | ||
| -$226.25M-5.9% | -$213.66M-17.6% | -$181.67M+3.6% | -$188.48M-8.7% | -$173.35M-8.6% | ||
| -$226.25M-5.9% | -$213.66M-17.6% | -$181.67M+3.6% | -$188.48M-8.7% | -$173.35M-8.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Celldex Therapeutics's cash flow data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.